Genmab Announces Financial Results for the Nine Months of 2026

Genmab reported revenue of $3.24 billion for the nine months ended September 30, 2026, up 22% year over year, with royalty revenue of $2.699 billion and EPKINLY/TEPKINLY global sales of $491 million. Operating profit was $986 million and net profit was $698 million. The company maintained its previously issued 2026 financial guidance and increased investment in its pipeline, including advancing Rina-S and petosemtamab.